Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending November 14, 2006. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a regulatory disclosure of specific share transactions and does not contain financial performance data.
Material Changes
The filing details specific transactions involving the SmithKline Beecham Employee Benefit Trust ("the Trust") on November 6, 2006:
- Share Sales: 436 Ordinary shares were sold on behalf of participants in the SmithKline Beecham Bonus Investment Plan at a price of GBP 14.05 per share.
- Share Transfers: 1,452 Ordinary shares were transferred from the Trust to a participant in the SmithKline Beecham Bonus Investment Plan.
Director Mr. J S Heslop is noted as having an interest in the shares held in the fund, consistent with other non-US employees or former employees.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the notification of the aforementioned share transactions in accordance with Disclosure Rule 3.1.4R(1)(b).
Key Facts for Investor Verification
- Verify the total number of shares held by the SmithKline Beecham Employee Benefit Trust following the reported sales and transfers.
- Confirm the current share price relative to the GBP 14.05 transaction price reported on November 6, 2006.
- Review the full composition of the Trust to understand the extent of Director J S Heslop's indirect interest.
- Check subsequent filings for any additional transactions by the Trust or related parties.